PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials-Reference-Cited by-同舟云学术

PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials

Published:2017-07 Issue: Volume:175 Page:91-106
ISSN:0163-7258
Container-title:Pharmacology & Therapeutics
language:en
Short-container-title:Pharmacology & Therapeutics

Author:

Dey Nandini,De Pradip,Leyland-Jones Brian

Funder

Genomic Oncology Institute, Department of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, SD

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference164 articles.

1. Safety and clinical activity of atezolizumab (anti-PD-L1) in combination with nabpaclitaxel in patients with metastatic triple-negative breast cancer;Adams,2015

2. Perturbations of the AKT signaling pathway in human cancer;Altomare;Oncogene,2005

3. The evolution of triple-negative breast cancer: From biology to novel therapeutics;Anders;American of Society of Clinical Oncology Educational Book,2016

4. Poly(ADP-ribose) polymerase inhibition: "Targeted" therapy for triple-negative breast cancer;Anders;Clinical Cancer Research,2010

5. Molecular alterations and everolimus efficacy in human epidermal growth factor receptor 2-overexpressing metastatic breast cancers: Combined exploratory biomarker analysis from BOLERO-1 and BOLERO-3;Andre;Journal of Clinical Oncology,2016

Cited by 159 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systemic inflammation and insulin resistance-related indicator predicts poor outcome in patients with cancer cachexia;Cancer & Metabolism;2024-01-25

2. Exploring the dynamic interplay between cancer stem cells and the tumor microenvironment: implications for novel therapeutic strategies;Journal of Translational Medicine;2023-10-02

3. Long non-coding RNA and the tumor microenvironment: Prospects for clinical applications in breast cancer;Critical Reviews in Oncology/Hematology;2023-10

4. SIRT2 inhibitor SirReal2 enhances anti‐tumor effects of PI3K/mTOR inhibitor VS‐5584 on acute myeloid leukemia cells;Cancer Medicine;2023-09

5. Recent advances in targeted strategies for triple-negative breast cancer;Journal of Hematology & Oncology;2023-08-28